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PEComas are a collection of generally rare tumors, defined by the World Health Organization as ‘mesenchymal
tumors composed of histologically and immunohistochemically distinctive perivascular epitheloid cells’. We describe
the case of retroperitoneal PEComa with a liposarcoma-like appearance on cross-sectional imaging, but distinctive
immunohistochemistry revealing the correct diagnosis.
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Perivascular Epitheloid Cell tumors (PEComas) are rare
mesenchymal tumors that can appear at various sites in
the body and can be associated with the tuberous sclerosis
complex. They can possess a heterogeneous appearance,
ranging from poorly differentiated soft-tissue tumors to
sclerosing masses. Lipid-rich PEComas are uncommon.
We present the case of a large lipid-rich PEComa pri-
marily misdiagnosed as a liposarcoma on computed
tomography and magnetic resonance imaging. Histology,
however, revealed a lipid-rich PEComa without any signs
of malignancy, which required no further treatment
following surgical resection.Case presentation
A 75-year-old man was referred for abdominal computed
tomography (CT) due to a poorly defined liver mass,
detected by the primary care physician on ultrasound
screening, which turned out to be a hemangioma. As an
accidental finding, the contrast-enhanced CT scan add-
itionally showed an 8 × 11 × 15 cm large retroperitoneal
mass in the lower left abdomen adjacent to the sigmoid
colon and the left psoas muscle (Figure 1A). The density
measurements revealed that the thinly encapsulated mass
consisted predominantly of fat with a few solid nodular
structures. Contrast-enhanced magnetic resonance imaging
(MRI) confirmed the lesion to be composed predominantly* Correspondence: moritz.wildgruber@tum.de
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article, unless otherwise stated.of fat with a few solid hypervascularized nodules (Figure 1B
and C). The mass was palpable through the abdominal wall
but painless. Laboratory findings indicated a mild anemia
(hemoglobin 12.9 g/dl) but were otherwise unremarkable.
The patient had no history of malignant or infectious
disease.
Due to the imaging findings, a retroperitoneal liposar-
coma was suspected and the patient underwent surgery
with resection of the mass and the adjacent sigmoid
colon. Intraoperatively, the tumor showed firm adhe-
sions both with the mesentery of the sigmoid colon as
well as with the adjacent small bowel mesentery. During
adhesiolysis, several tumor feeding vessel originating
from the inferior mesenteric artery were identified and
clamped. Due to the close proximity of the tumor to the
sigmoid colon, the latter was resected en bloc together
with the mass and a side-to-side descendo-rectostomy
was performed. Macroscopic appearance as well as hist-
ology and immunohistochemistry of the mass are shown
in Figure 2.
Macroscopic evaluation of the surgical specimen
confirmed the predominance of fat within the thinly
encapsulated tumor (Figure 2A). Histology demonstrated
the presence of large-sized lipid vacuoles and small,
disseminated islands of lipoblasts (Figure 2B). Variable-
sized nests of epitheloid cells were spread over the
tumor. Immunohistochemically, these cells showed only
weak staining for melan-A, desmin and smooth muscle
actin (SMA) (Figure 2C). S-100 staining was negative
but strong reaction was found for human melanoma
black HMB-45 (Figure 2D). MiB1 staining revealed atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Computed tomography (A) and magnetic resonance imaging findings (B and C) demonstrate an ovoid encapsulated
retroperitoneal mass, which contained predominantly fat and a few solid hypervascularized nodules (arrows).
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fluorescence in situ hybridization (FISH) for MDM2
gene amplification was negative, thus a liposarcoma
was ruled out and the final diagnosis was lipid-rich
perivascular epitheloid cell tumor (PEComa) without
any signs of malignancy. The patient recovered well
from surgery and did not require any further adjuvant
treatment.
Discussion
PEComas are a rare mesenchymal tumor entity
incorporating angiomyolipomas, clear ‘sugar’ cell tu-
mors, lymphangioleiomyomas and histologically and
immunophenotypically similar tumors occurring at
various soft-tissue and visceral sites, and can beFigure 2 Macroscopic appearance (A) and histology with H&E stainin
(C) and human melanoma black (HMB)-45 (D).associated with the tuberous sclerosis complex [1,2].
Distinctive epitheloid tumor cells show a focal associ-
ation with blood vessels and express melanocytic and
smooth muscle markers, the most sensitive being
HMB-45 [3,4].
PEComas have been described at various extrarenal
locations including the mesentery, urinary bladder,
liver, pancreas, rectum, heart and lung as well as in
the bone [5-11]. Retroperitoneal localization of PEComas
has been described [12,13], but a liposarcoma-like
aspect of the tumor in this localization as in our
case is extremely rare. PEComas occurring in these
non-classical locations have been termed ‘perivascu-
lar epitheloid cell tumors not otherwise specified’
(PEComa-NOS) [14,15].g (B) and immunohistochemistry (IHC) for smooth muscle actin
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although a few common features have been described.
Mostly, PEComas have well defined borders and are of
regular shape. The enhancement on cross-sectional
imaging after contrast agent administration is usually
inhomogeneous due to the heterogeneous composition
of the tumor [16].
The degree of malignancy is highly variable in PECo-
mas, but as with other sarcomas, the size of the primary
tumor as well as the mitotic rate seem to be the most
reliable prognostic factors associated with recurrence
after surgical resection. Bleeker et al. have recently
established a suggestion for risk stratification and treat-
ment strategies [14]. If possible, surgical resection is the
treatment of choice for PEComas and, as activation of
the mTOR signaling pathway is common in these
tumors, mTOR inhibitors such as rapamycin have been
successfully applied as medical treatment . Although no
large series of patients treated with mTOR inhibitors
exist, preliminary data suggest that complete response is
possible [17].
With a size > 5 cm but absent further risk factors such
as infiltrative growth pattern, high nuclear grade and
cellularity, mitotic rate > 1/50 HPF, necrosis or vascular
invasion, the tumor in our patient was stratified as
‘uncertain malignant potential’ according to the modified
Folpe criteria [14]. According to these criteria, adjuvant
therapy may be of benefit in patients with high risk of
recurrence, which was not considered to be present in
our patient. However, regardless of the postoperative
strategy employed, long-term surveillance should be at
its core, as recurrences have been reported more than
five years following resection [14]. Our patient is sched-
uled for clinical follow-up evaluation every six months
for the first five years and, similar to sarcoma patients,
with contrast-enhanced MRI every six months in the
first three years and subsequent annual MRI examina-
tions thereafter. Today, one and a half years after surgi-
cal resection, the patient is free of recurrence.
Conclusion
Although a rare tumor entity, PEComas are occasionally
found as usually well-circumscribed tumors, often
located in the abdomen, retroperitoneum or the pelvis.
Besides surgical resection as the treatment option of
choice, clinicians should be aware of new treatment
strategies using inhibitors of the mTOR signaling path-
way, which is commonly activated in PEComas.
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